Citadel Advisors
AXNX

Citadel Advisors’s Axonics, Inc. Common Stock AXNX Stock Holding History

Citadel Advisors’s Portfolio AXNX Stock Details AXNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-5,200
Closed -$362K – 15691
2024
Q3 		$362K Sell
5,200
-200
-4% -$13.7K ﹤0.01% 8919
2024
Q2 		$363K Sell
5,400
-3,100
-36% -$209K ﹤0.01% 8728
2024
Q1 		$586K Sell
8,500
-1,500
-15% -$101K ﹤0.01% 8033
2023
Q4 		$622K Sell
10,000
-20,800
-68% -$1.16M ﹤0.01% 7629
2023
Q3 		$1.73M Buy
30,800
+10,800
+54% +$608K ﹤0.01% 5493
2023
Q2 		$1.01M Buy
20,000
+12,200
+156% +$649K ﹤0.01% 6437
2023
Q1 		$426K Sell
7,800
-4,700
-38% -$275K ﹤0.01% 8639
2022
Q4 		$782K Buy
12,500
+7,400
+145% +$491K ﹤0.01% 7306
2022
Q3 		$359K Sell
5,100
-300
-6% -$20.7K ﹤0.01% 9192
2022
Q2 		$306K Sell
5,400
-9,600
-64% -$526K ﹤0.01% 9759
2022
Q1 		$939K Sell
15,000
-6,200
-29% -$334K ﹤0.01% 7851
2021
Q4 		$1.19M Sell
21,200
-18,300
-46% -$1.12M ﹤0.01% 7527
2021
Q3 		$2.57M Sell
39,500
-12,300
-24% -$839K ﹤0.01% 5738
2021
Q2 		$3.29M Buy
51,800
+9,100
+21% +$537K ﹤0.01% 5379
2021
Q1 		$2.56M Buy
42,700
+21,400
+100% +$1.16M ﹤0.01% 5810
2020
Q4 		$1.06M Buy
21,300
+11,600
+120% +$545K ﹤0.01% 6684
2020
Q3 		$495K Sell
9,700
-200
-2% -$8.35K ﹤0.01% 7322
2020
Q2 		$348K Sell
9,900
-16,100
-62% -$555K ﹤0.01% 7675
2020
Q1 		$661K Buy
26,000
+9,400
+57% +$280K ﹤0.01% 6016
2019
Q4 		$460K Buy
+16,600
New +$396K ﹤0.01% 6954

Other funds holding AXNX

TCA
Taconic Capital Advisors New York $229M AUM 110.07% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Citadel Advisors's AXNX Position: Q4 2024 in Review

Citadel Advisors sold out of Axonics, Inc. Common Stock (AXNX) in Q4 2024, closing a stake of 170,323 shares — an estimated $11.9M sold.

Citadel Advisors first reported a position in AXNX in Q4 2018 and held it in 24 quarters. The position peaked at $46M in Q1 2021. 2 funds tracked by Wall St. Rank hold AXNX as of Q4 2024.

  • Citadel Advisors reported no remaining Axonics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Citadel Advisors sold 170,323 Axonics, Inc. Common Stock shares in Q4 2024, an estimated $11.9M.
  • Citadel Advisors first reported a position in Axonics, Inc. Common Stock in Q4 2018 and held it in 24 quarters.
  • Citadel Advisors's Axonics, Inc. Common Stock position peaked at $46M in Q1 2021.
  • 2 funds tracked by Wall St. Rank held Axonics, Inc. Common Stock as of Q4 2024.

Based on Citadel Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.